This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Concordia asks UK court for CMA drug-probe freeze pending Pfizer, Flynn appeal outcome

By Victoria Ibitoye ( June 11, 2019, 18:06 GMT | Insight) -- Drugmaker Concordia has called for a UK antitrust probe into its pricing of liothyronine tablets to be halted while the law governing the pricing of generic medicines is clarified. The London-based company said it should not be required to respond to the Competition and Markets Authority’s supplementary statement of objections, or SSO, until the Court of Appeal rules on a challenge by the regulator in a dispute involving Pfizer and Flynn Pharma.Drugmaker Concordia has called for a UK antitrust probe into its pricing of liothyronine tablets to be halted while the law governing the pricing of generic medicines is clarified....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections